Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Nov 1;7(44):71951-71959.
doi: 10.18632/oncotarget.12442.

Secondary malignancies after partial versus whole breast irradiation: a systematic review and meta-analysis

Xin-Bin Pan  1 , Shi-Ting Huang  1 , Yan-Ming Jiang  1 , Jia-Lin Ma  1 , Xiao-Dong Zhu  1
Affiliations
Meta-Analysis

Secondary malignancies after partial versus whole breast irradiation: a systematic review and meta-analysis

Xin-Bin Pan et al. Oncotarget. .

Abstract

Secondary malignancies are a common complication for patients receiving radiotherapy. Here, we compared rates of secondary malignancies after partial breast irradiation (PBI) and whole breast irradiation (WBI). The MEDLINE, EMBASE, and the Cochrane Library databases were systematically searched to identify relevant randomized clinical trials comparing PBI with WBI in breast cancer patients treated with breast-conserving therapy. Four studies including 2,185 patients were selected. Compared to WBI, the pooled odds ratios (OR) for contralateral breast cancer were 0.86 (95% confidence interval (CI) 0.31-2.42; p = 0.78) after 5 years and 1.15 (95% CI 0.43-3.09; p = 0.78) after 10 years for PBI. The pooled ORs for secondary non-breast cancer were 0.91 (95% CI 0.49-1.67; p = 0.77) after 5 years and 1.20 (95% CI 0.39-3.66; p = 0.75) after 10 years for PBI compared to WBI. These results demonstrate that the risk of secondary malignancies is similar for PBI and WBI after breast-conserving radiotherapy.

Keywords: breast cancer; breast-conserving therapy; partial breast irradiation; secondary malignancies; whole breast irradiation.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. Flowchart depicting the study selection process
Figure 2
Figure 2. Pooled odds ratios for contralateral breast cancer within 5 years of partial versus whole breast irradiation
Figure 3
Figure 3. Pooled odds ratios for contralateral breast cancer within 10 years of partial versus whole breast irradiation
Figure 4
Figure 4. Pooled odds ratios for secondary non-breast cancer within 5 years of partial versus whole breast irradiation
Figure 5
Figure 5. Pooled odds ratios for secondary non-breast cancer within 10 years of partial versus whole breast irradiation
See this image and copyright information in PMC

References

    1. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, Naghavi M. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378:1461–84. doi: 10.1016/S0140-673661351-2. - DOI - PubMed
    1. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106. doi: 10.1016/S0140-673667887-7. - DOI - PubMed
    1. Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16. doi: 10.1016/S0140-673661629-2. - DOI - PMC - PubMed
    1. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, Kamby C, Kjaer M, Gadeberg CC, Rasmussen BB, Blichert-Toft M, Mouridsen HT. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–8. doi: 10.1016/S0140-673609201-0. - DOI - PubMed
    1. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, Zedeler K. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949–55. doi: 10.1056/NEJM199710023371401. - DOI - PubMed